Miyazaki R, Tamura M, Sakai T, Furukawa N, Yamamoto M, Okada H
J Thorac Dis. 2024; 16(7):4400-4408.
PMID: 39144366
PMC: 11320273.
DOI: 10.21037/jtd-24-435.
Almeida-Nunes D, Nunes M, Osorio H, Ferreira V, Lobo C, Monteiro P
Biochem Biophys Rep. 2024; 39:101755.
PMID: 38974022
PMC: 11225207.
DOI: 10.1016/j.bbrep.2024.101755.
Marin A, Filipescu A, Petca A
Cureus. 2024; 16(4):e59219.
PMID: 38807790
PMC: 11132319.
DOI: 10.7759/cureus.59219.
Zhang W, Zhang Z, Qian L
World J Surg Oncol. 2024; 22(1):8.
PMID: 38172843
PMC: 10763048.
DOI: 10.1186/s12957-023-03290-5.
Zhang C, Jiang X, Li Y, Pan X, Gao M, Chen Y
J Ovarian Res. 2023; 16(1):36.
PMID: 36759864
PMC: 9912515.
DOI: 10.1186/s13048-023-01116-2.
Data-Independent Acquisition and Parallel Reaction Monitoring Mass Spectrometry Identification of Serum Biomarkers for Ovarian Cancer.
Rauniyar N, Peng G, Lam T, Zhao H, Mor G, Williams K
Biomark Insights. 2017; 12:1177271917710948.
PMID: 28615921
PMC: 5462478.
DOI: 10.1177/1177271917710948.
Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
Roncolato F, Joly F, OConnell R, Lanceley A, Hilpert F, Buizen L
Oncologist. 2017; 22(9):1117-1124.
PMID: 28596446
PMC: 5599194.
DOI: 10.1634/theoncologist.2017-0047.
Expression of C-Reactive Protein in Rectal Cancer.
Contu P, Contu S, Rosito M, Moreira L
Gastroenterology Res. 2016; 2(2):104-109.
PMID: 27956962
PMC: 5139826.
DOI: 10.4021/gr2009.03.1279.
Impact of Body Weight and Body Composition on Ovarian Cancer Prognosis.
Purcell S, Elliott S, Kroenke C, Sawyer M, Prado C
Curr Oncol Rep. 2016; 18(2):8.
PMID: 26769113
DOI: 10.1007/s11912-015-0488-3.
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.
Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C
PLoS One. 2015; 10(12):e0143080.
PMID: 26717416
PMC: 4705106.
DOI: 10.1371/journal.pone.0143080.
Wheel Balanced Cancer Therapy for Longer Than 21 Days Can Have a Positive Effect on the Survival of Patients with Stage IV Cancer.
Jeon H, Kim J, Cho C, Lee Y, Yoo H
J Pharmacopuncture. 2015; 18(3):19-31.
PMID: 26388999
PMC: 4573804.
DOI: 10.3831/KPI.2015.18.021.
Evaluation correlates C-reactive protein with advanced stage Hodgkin's lymphoma and response to treatment in a tertiary university hospital in Brazil.
Rocha T, Miranda Silva A, Fortier S, Chiattone C
Rev Bras Hematol Hemoter. 2015; 37(4):242-6.
PMID: 26190427
PMC: 4519702.
DOI: 10.1016/j.bjhh.2015.05.003.
Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios.
Yildirim M, Cendek B, Avsar A
Mol Clin Oncol. 2015; 3(2):317-321.
PMID: 25798260
PMC: 4360876.
DOI: 10.3892/mco.2014.481.
Urinary interleukin-1β levels among gynecological patients.
Woolery K, Hoffman M, Kraft J, Nicosia S, Kumar A, Kruk P
J Ovarian Res. 2014; 7:104.
PMID: 25403235
PMC: 4247195.
DOI: 10.1186/s13048-014-0104-4.
Interleukin-6 (IL-6) and C-reactive protein (CRP) concentration prior to total nephrectomy are prognostic factors in localized renal cell carcinoma (RCC).
Hrab M, Olek-Hrab K, Antczak A, Kwias Z, Milecki T
Rep Pract Oncol Radiother. 2014; 18(5):304-9.
PMID: 24416568
PMC: 3863166.
DOI: 10.1016/j.rpor.2013.06.002.
Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer.
Watanabe T, Shibata M, Nishiyama H, Soeda S, Furukawa S, Gonda K
Oncol Lett. 2014; 7(2):373-377.
PMID: 24396450
PMC: 3881702.
DOI: 10.3892/ol.2013.1735.
Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy.
Maria T, Vasileios K, Panagiotis P, Kostas S
Int J Clin Exp Med. 2012; 6(1):50-6.
PMID: 23236558
PMC: 3515978.
Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer.
Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y
Exp Ther Med. 2012; 2(5):879-885.
PMID: 22977592
PMC: 3440840.
DOI: 10.3892/etm.2011.308.
Effect of high-dose intravenous vitamin C on inflammation in cancer patients.
Mikirova N, Casciari J, Rogers A, Taylor P
J Transl Med. 2012; 10:189.
PMID: 22963460
PMC: 3480897.
DOI: 10.1186/1479-5876-10-189.
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.
Hiss D
J Oncol. 2012; 2012:737981.
PMID: 22481932
PMC: 3306947.
DOI: 10.1155/2012/737981.